(Q55041984)

16 June 2018

title

Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. (English)

1 reference

16 June 2018

author name string

Katayama K

1

1 reference

16 June 2018

Nomura S

2

1 reference

16 June 2018

Ishikawa H

3

1 reference

16 June 2018

Murata T

4

1 reference

16 June 2018

Koyabu S

5

1 reference

16 June 2018

Nakano T

6

1 reference

16 June 2018

language of work or name

English

0 references

publication date

17 May 2006

1 reference

16 June 2018

published in

Kidney International

1 reference

16 June 2018

volume

70

1 reference

16 June 2018

issue

1

1 reference

16 June 2018

page(s)

151-156

1 reference

16 June 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Differential effects of calcium antagonist subclasses on markers of nephropathy progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Progression, remission, regression of chronic renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000349

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000349

1 reference

16 June 2018

Dimensions Publication ID

1043541375

0 references

1 reference

16 June 2018